Apr/10/2007 06:09 Filed in:
Pharma
Business
Could Pfizer
have an expensive failure on their hands with
Exubera, the first inhaled insulin? It seems like
a lot of people think so including some Wall
Street analysts who are revising the sales
forecast for Exubera way down. Pfizer has changed
the selling of Exubera from the pain management
division to the CV division but what Pfizer
hasn't learned that in order for a product to be
adopted by the market it needs to be easy to use
and convenient. Exubera unfortunately doesn't
have any of these traits and companies like Lilly
which have inhaled insulin in development are
taking notes from Pfizer's mistakes.
Read
More...
Tags: Pfizer
